Paraproteinaemia in Primary Cutaneous Marginal Zone Lymphoma

Autor: Alexander Strate, Kristina Röding, Eva Geissinger, Hermann Kneitz, Marion Wobser, Sabine Roth, Verena G Frings, Andreas Rosenwald, Matthias Goebeler
Rok vydání: 2018
Předmět:
Adult
Male
Immunofixation
Pathology
medicine.medical_specialty
Skin Neoplasms
Paraproteinemias
lymphoma
Dermatology
Serology
030207 dermatology & venereal diseases
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
hemic and lymphatic diseases
Lactate dehydrogenase
lcsh:Dermatology
medicine
Humans
Aged
Retrospective Studies
Aged
80 and over

medicine.diagnostic_test
biology
business.industry
monoclonalgammopathy
immunofixation
Lymphoma
B-Cell
Marginal Zone

General Medicine
lcsh:RL1-803
Middle Aged
Marginal zone
medicine.disease
Lymphoma
Immunoglobulin M
chemistry
Immunoglobulin G
030220 oncology & carcinogenesis
Serum protein electrophoresis
biology.protein
Primary cutaneous marginal zone lymphoma
Female
Immunoglobulin Light Chains
Paraproteins
Neoplasm Recurrence
Local

Immunoglobulin Heavy Chains
business
monoclonalimmunoglobulins
Follow-Up Studies
Zdroj: Acta Dermato-Venereologica, Vol 98, Iss 10, Pp 956-962 (2018)
ISSN: 0001-5555
DOI: 10.2340/00015555-3016
Popis: Primary cutaneous marginal zone lymphomas (PCMZL) frequently exhibit lymphoplasmacytoid/plasmacytic differentiation, implying the capacity to produce monoclonal immunoglobulins. As these paraproteins are secreted, and thus are measurable in blood and urine, they may correlate with disease burden and serve as tumour markers reflecting therapeutic response. This study retrospectively analysed the records of 23 patients with PCMZL. During treatment and follow-up, laboratory tests, including full blood count, lactate dehydrogenase, serum protein electrophoresis and turbidimetric analyses, were conducted. Thirty-nine percent of cases showed a suspicious serum protein electrophoresis in terms of paraproteinaemia. In 44% of cases the heavy and light chain restriction in tissue samples correlated with serological findings. Altogether, 89% of the PCMZL patients with paraproteinaemia eventually experienced a relapse, in contrast to 62% of the group without paraproteinaemia. This study analysed the incidence and clinical implications of paraproteinaemia in patients with PCMZL. A clear correlation was found between paraproteinaemia, tumour relapse and therapeutic intervention.
Databáze: OpenAIRE